Covered recipient · General Payments record
ALAN J KIVITZ
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$131,318.71
366 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $56,414.00 | 14 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $52,073.00 | 27 |
| Honoraria | $15,280.00 | 5 |
| Food and Beverage | $5,460.42 | 313 |
| Travel and Lodging | $1,988.11 | 5 |
| Education | $103.18 | 2 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $47,925.79 | 35 |
| Lilly USA, LLC | $19,135.03 | 22 |
| GlaxoSmithKline, LLC. | $16,452.60 | 24 |
| UCB, Inc. | $14,306.66 | 35 |
| Horizon Therapeutics plc | $7,824.78 | 31 |
| Amgen Inc. | $7,467.68 | 37 |
| AbbVie Inc. | $7,120.67 | 53 |
| GENZYME CORPORATION | $4,951.15 | 12 |
| SANOFI US SERVICES INC. | $2,204.00 | 1 |
| UCB SA | $1,380.00 | 1 |
| Janssen Biotech, Inc. | $1,166.22 | 53 |
| Novartis Pharmaceuticals Corporation | $486.16 | 23 |
| AstraZeneca Pharmaceuticals LP | $179.98 | 6 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $142.64 | 5 |
| Mallinckrodt Hospital Products Inc. | $94.68 | 6 |
| SANOFI-AVENTIS U.S. LLC | $89.00 | 1 |
| Ultragenyx Pharmaceutical Inc. | $71.82 | 5 |
| E.R. Squibb & Sons, L.L.C. | $68.31 | 4 |
| Aurinia Pharma U.S., Inc. | $66.29 | 2 |
| Janssen Scientific Affairs, LLC | $56.36 | 1 |
| Genentech USA, Inc. | $37.96 | 3 |
| Sobi, Inc | $37.61 | 3 |
| Pacira Therapeutics, Inc. | $36.78 | 2 |
| Antares Pharma, Inc. | $16.54 | 1 |
Page 2 of 8; records 51–100 of 366 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ALAN J KIVITZ
NPI 1447259023 · CMS profile ID 291961
Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology
DUNCANSVILLE, PA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 8; records 51–100 of 366 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1447259023?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ALAN J KIVITZ, NPI 1447259023, CMS profile ID 291961. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 8; records 51–100 of 366 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447259023?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). ALAN J KIVITZ, NPI 1447259023, CMS profile ID 291961. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 8; records 51–100 of 366 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447259023?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- ALAN J KIVITZ, NPI 1447259023, CMS profile ID 291961, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 8; records 51–100 of 366 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1447259023?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
366 matching records · $131,318.71 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 366.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AbbVie Inc. | $21.15 | 11/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795116888 | CMS |
| Janssen Biotech, Inc. | $1.23 | 11/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788244491 | CMS |
| GENZYME CORPORATION | $7.69 | 11/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843400637 | CMS |
| SANOFI-AVENTIS U.S. LLC | $89.00 | 11/11/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843400635 | CMS |
| Horizon Therapeutics plc | $9.62 | 11/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797159315 | CMS |
| Lilly USA, LLC | $14.43 | 11/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818923629 | CMS |
| AbbVie Inc. | $5.08 | 11/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795116885 | CMS |
| Mallinckrodt Hospital Products Inc. | $12.52 | 11/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845364119 | CMS |
| Novartis Pharmaceuticals Corporation | $14.75 | 11/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812753357 | CMS |
| Janssen Biotech, Inc. | $22.74 | 11/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788244493 | CMS |
| AbbVie Inc. | $5.56 | 11/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795116881 | CMS |
| Amgen Inc. | $26.00 | 11/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825117777 | CMS |
| AbbVie Inc. | $16.53 | 10/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795116877 | CMS |
| GlaxoSmithKline, LLC. | $43.98 | 10/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 803147553 | CMS |
| Janssen Biotech, Inc. | $16.11 | 10/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788244417 | CMS |
| Amgen Inc. | $19.24 | 10/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825117823 | CMS |
| AbbVie Inc. | $2.20 | 10/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795116873 | CMS |
| PFIZER INC. | $15.88 | 10/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833251549 | CMS |
| Lilly USA, LLC | $16.32 | 10/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818915777 | CMS |
| AbbVie Inc. | $15.90 | 10/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795116869 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $10.08 | 10/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763343972 | CMS |
| PFIZER INC. | $3,500.00 | 10/22/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833394829 | CMS |
| GlaxoSmithKline, LLC. | $14.31 | 10/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 803058493 | CMS |
| PFIZER INC. | $27.47 | 10/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832956477 | CMS |
| Amgen Inc. | $18.14 | 10/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825117733 | CMS |
| Novartis Pharmaceuticals Corporation | $55.01 | 10/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812753321 | CMS |
| Amgen Inc. | $22.09 | 10/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825117773 | CMS |
| PFIZER INC. | $1.04 | 10/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832880249 | CMS |
| PFIZER INC. | $11.90 | 10/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832887069 | CMS |
| Ultragenyx Pharmaceutical Inc. | $15.97 | 10/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848963881 | CMS |
| AbbVie Inc. | $14.88 | 10/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795116865 | CMS |
| GlaxoSmithKline, LLC. | $62.00 | 10/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802449433 | CMS |
| Janssen Biotech, Inc. | $19.04 | 10/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788244501 | CMS |
| UCB, Inc. | $12.94 | 10/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807410561 | CMS |
| Ultragenyx Pharmaceutical Inc. | $14.98 | 10/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848963879 | CMS |
| AbbVie Inc. | $19.69 | 10/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795116861 | CMS |
| Novartis Pharmaceuticals Corporation | $14.78 | 10/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812753355 | CMS |
| Mallinckrodt Hospital Products Inc. | $17.45 | 10/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845364117 | CMS |
| AbbVie Inc. | $13.42 | 10/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795116857 | CMS |
| Janssen Biotech, Inc. | $14.02 | 10/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788244415 | CMS |
| Lilly USA, LLC | $688.27 | 09/30/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818894295 | CMS |
| Amgen Inc. | $15.87 | 09/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825117819 | CMS |
| Horizon Therapeutics plc | $24.92 | 09/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797159307 | CMS |
| Horizon Therapeutics plc | $3,240.00 | 09/28/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797159309 | CMS |
| Horizon Therapeutics plc | $48.16 | 09/28/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797159311 | CMS |
| Horizon Therapeutics plc | $124.99 | 09/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797159313 | CMS |
| AbbVie Inc. | $5.66 | 09/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795116853 | CMS |
| PFIZER INC. | $13.97 | 09/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833251565 | CMS |
| AbbVie Inc. | $17.39 | 09/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795116849 | CMS |
| GlaxoSmithKline, LLC. | $17.52 | 09/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802904139 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $509.29 | 1 |
| PY2025 | Principal investigator | $5,331,984.99 | 289 |
| PY2024 | Recipient | $12,476.88 | 4 |
| PY2024 | Principal investigator | $3,675,816.60 | 217 |
| PY2023 | Recipient | $5,547.39 | 4 |
| PY2023 | Principal investigator | $3,137,369.25 | 336 |
| PY2022 | Recipient | $3,324.00 | 5 |
| PY2022 | Principal investigator | $3,646,712.77 | 293 |
| PY2021 | Recipient | $11,588.00 | 9 |
| PY2021 | Principal investigator | $3,875,897.77 | 384 |
| PY2020 | Recipient | $34,397.13 | 32 |
| PY2020 | Principal investigator | $3,237,261.65 | 498 |
| PY2019 | Recipient | $48,731.74 | 28 |
| PY2019 | Principal investigator | $3,234,791.65 | 442 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
290 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $834.57 | 12/31/2025 | Non-covered Recipient Entity Altoona Center for Clinical Research PC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228749030 |
| Principal investigator 1 | ModernaTX, Inc. | $1,440.00 | 12/22/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968837 |
| Principal investigator 1 | ModernaTX, Inc. | $2,846.41 | 12/19/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968787 |
| Principal investigator 1 | ModernaTX, Inc. | $315.31 | 12/19/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968797 |
| Principal investigator 1 | ModernaTX, Inc. | $9,741.40 | 12/19/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968819 |
| Principal investigator 1 | ModernaTX, Inc. | $1,950.00 | 12/19/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968849 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,022.95 | 12/19/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223290028 |
| Principal investigator 1 | ABBVIE INC. | $336.00 | 12/18/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARC | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202531150 |
| Principal investigator 1 | PFIZER INC. | $8,845.70 | 12/17/2025 | Non-covered Recipient Entity Altoona Center for Clinical Research PC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228747193 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $13,683.95 | 12/17/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223289884 |
| Principal investigator 1 | PFIZER INC. | $36,262.49 | 12/16/2025 | Non-covered Recipient Entity Altoona Center for Clinical Research PC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228725560 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 12/15/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEAR | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175303283 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,563.00 | 12/15/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEAR | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175303384 |
| Principal investigator 1 | Janssen Research & Development, LLC | $746.26 | 12/15/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEAR | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-nave Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175303394 |
| Principal investigator 1 | ABBVIE INC. | $288.00 | 12/11/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARC | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202530014 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500.00 | 12/05/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223289332 |
| Principal investigator 1 | ABBVIE INC. | $3,000.00 | 12/04/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) | No dispute reported | 06/30/2026 | 1202526440 |
| Principal investigator 1 | ABBVIE INC. | $1,932.65 | 12/04/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARC | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202526930 |
| Principal investigator 1 | ABBVIE INC. | $18,232.32 | 12/04/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARC | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202526932 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 12/04/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184269113 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $750.00 | 12/04/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184269115 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $50.00 | 12/04/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184269117 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $650.00 | 12/04/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184269119 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $82.60 | 12/01/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223288955 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,118.60 | 12/01/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223289118 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,135.00 | 11/27/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175264998 |
| Principal investigator 1 | Janssen Research & Development, LLC | $68.00 | 11/27/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265013 |
| Principal investigator 1 | Janssen Research & Development, LLC | $271.00 | 11/27/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265033 |
| Principal investigator 1 | Janssen Research & Development, LLC | $68.00 | 11/27/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265053 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,290.00 | 11/27/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265168 |
| Principal investigator 1 | Janssen Research & Development, LLC | $35.00 | 11/26/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175264980 |
| Principal investigator 1 | Janssen Research & Development, LLC | $35.00 | 11/26/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265007 |
| Principal investigator 1 | Janssen Research & Development, LLC | $35.00 | 11/26/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265040 |
| Principal investigator 1 | Janssen Research & Development, LLC | $35.00 | 11/26/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265101 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,376.82 | 11/25/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184264473 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $18.55 | 11/20/2025 | Non-covered Recipient Entity Altoona Center For Clinical Research | A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1) | No dispute reported | 06/30/2026 | 1235999089 |
| Principal investigator 1 | Eli Lilly and Company | $1,020.92 | 11/19/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY4065967 FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1187874679 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,492.52 | 11/17/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEAR | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175303263 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $34.15 | 11/15/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH | A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease | No dispute reported | 06/30/2026 | 1190303117 |
| Principal investigator 1 | ABBVIE INC. | $549.00 | 11/13/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARC | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202524243 |
| Principal investigator 1 | PFIZER INC. | $19,360.33 | 11/13/2025 | Non-covered Recipient Entity Altoona Center for Clinical Research PC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228720559 |
| Principal investigator 1 | ABBVIE INC. | $992.00 | 11/12/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARC | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202523889 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $282.92 | 11/07/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258881 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,644.00 | 11/07/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258883 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,911.00 | 11/07/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258885 |
| Principal investigator 1 | ABBVIE INC. | $10,215.56 | 11/05/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARC | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202522647 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,507.40 | 11/05/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192147855 |
| Principal investigator 1 | ABBVIE INC. | $3,669.30 | 11/04/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARC | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202520873 |
| Principal investigator 1 | Janssen Research & Development, LLC | $600.00 | 10/31/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEAR | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175303233 |
| Principal investigator 1 | Janssen Research & Development, LLC | $430.86 | 10/30/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEAR | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175303249 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 10/30/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEAR | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175303401 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,188.41 | 10/29/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184253560 |
| Principal investigator 1 | Janssen Research & Development, LLC | $651.78 | 10/27/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEAR | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175303256 |
| Principal investigator 1 | ModernaTX, Inc. | $3,080.37 | 10/27/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968815 |
| Principal investigator 1 | ModernaTX, Inc. | $4,169.90 | 10/27/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968823 |
| Principal investigator 1 | ModernaTX, Inc. | $6,621.51 | 10/27/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968829 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,984.52 | 10/23/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184252468 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000.00 | 10/22/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCHPC | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223287245 |
| Principal investigator 1 | ABBVIE INC. | $168.00 | 10/16/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARC | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202517267 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $11,619.03 | 10/16/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184250595 |
| Principal investigator 1 | ABBVIE INC. | $5,452.10 | 10/09/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARC | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202513741 |
| Principal investigator 1 | ABBVIE INC. | $4,257.94 | 10/09/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARC | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202515547 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10,568.40 | 10/09/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184248862 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,777.05 | 10/03/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184244523 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,150.00 | 10/01/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223286049 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 09/25/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEAR CH PC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175303242 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 09/25/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEAR CH PC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175303332 |
| Principal investigator 1 | Janssen Research & Development, LLC | $160.00 | 09/25/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEAR CH PC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175303366 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,055.91 | 09/23/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184241828 |
| Principal investigator 1 | Janssen Research & Development, LLC | $989.92 | 09/22/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEAR CH PC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175303298 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,911.92 | 09/18/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184240822 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 09/15/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968825 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $84,218.09 | 09/10/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184235843 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $500.00 | 09/10/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223285253 |
| Principal investigator 1 | ABBVIE INC. | $12,500.00 | 09/04/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARC | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202508950 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,152.30 | 09/04/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184235359 |
| Principal investigator 1 | ABBVIE INC. | $1,509.50 | 09/03/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARC | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202507461 |
| Principal investigator 1 | ModernaTX, Inc. | $265.20 | 09/01/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968789 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,112.64 | 08/26/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184230649 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $506.35 | 08/21/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184229715 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,510.45 | 08/20/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223284383 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,937.92 | 08/14/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184228281 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $750.00 | 08/11/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192181636 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,000.00 | 08/07/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A PHASE IB, DOSE ESCALATION, OPEN LABEL STUDY TO EVALUATE THE SAFETY, | No dispute reported | 06/30/2026 | 1192181640 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,519.05 | 08/07/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184226109 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,555.00 | 08/07/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184226111 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $750.00 | 08/07/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184226113 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,911.00 | 08/07/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184226115 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,250.00 | 08/07/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184226117 |
| Principal investigator 1 | PFIZER INC. | $480.00 | 08/06/2025 | Non-covered Recipient Entity Altoona Center for Clinical Research PC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228767259 |
| Principal investigator 1 | ABBVIE INC. | $4,831.80 | 08/05/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARC | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202501346 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,507.40 | 08/01/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192181631 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,608.25 | 08/01/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223283421 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,012.70 | 07/31/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184222744 |
| Principal investigator 1 | Amgen Inc. | $1,437.84 | 07/28/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH - 175 MEADOWBROOK LN | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246639083 |
| Principal investigator 1 | ModernaTX, Inc. | $1,026.79 | 07/28/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968781 |
| Principal investigator 1 | ModernaTX, Inc. | $290.08 | 07/28/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968783 |
| Principal investigator 1 | ModernaTX, Inc. | $315.31 | 07/28/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968801 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,350.00 | 07/28/2025 | Non-covered Recipient Entity Altoona Center For Clinical Research PC Corp | A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1226137059 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 07/23/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265133 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 07/23/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265155 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 07/23/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265223 |
| Principal investigator 1 | PFIZER INC. | $375.98 | 07/23/2025 | Non-covered Recipient Entity Altoona Center for Clinical Research PC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228763720 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,863.14 | 07/22/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184217621 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,822.00 | 07/22/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184217623 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,822.00 | 07/22/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184217627 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $125.34 | 07/22/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184217629 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10.86 | 07/22/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184217631 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,911.00 | 07/22/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184217633 |
| Principal investigator 1 | UCB SA | $6,381.60 | 07/21/2025 | Non-covered Recipient Entity WEITZNER, YONKER, KAINE MD. | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | No dispute reported | 06/30/2026 | 1246657870 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,444.27 | 07/17/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184217000 |
| Principal investigator 1 | PFIZER INC. | $108.00 | 07/16/2025 | Non-covered Recipient Entity Altoona Center for Clinical Research PC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228765238 |
| Principal investigator 1 | ModernaTX, Inc. | $1,760.00 | 07/14/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968817 |
| Principal investigator 1 | PFIZER INC. | $8,537.98 | 07/11/2025 | Non-covered Recipient Entity Altoona Center for Clinical Research PC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228773516 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,257.42 | 07/10/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184214266 |
| Principal investigator 1 | ABBVIE INC. | $1,200.00 | 07/09/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARC | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202497598 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,000.00 | 07/03/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEAR CH PC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-nave Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175303324 |
| Principal investigator 1 | ABBVIE INC. | $13,500.00 | 07/02/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARC | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202494927 |
| Principal investigator 1 | ABBVIE INC. | $4,042.90 | 07/02/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARC | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202495897 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,063.00 | 07/02/2025 | Non-covered Recipient Entity Altoona Center For Clinical Research PC Corp | A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1226137036 |
| Principal investigator 1 | Janssen Research & Development, LLC | $68.00 | 06/30/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265150 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,757.00 | 06/30/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265182 |
| Principal investigator 1 | ModernaTX, Inc. | $772.20 | 06/27/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968791 |
| Principal investigator 1 | ModernaTX, Inc. | $10,089.92 | 06/27/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968793 |
| Principal investigator 1 | ModernaTX, Inc. | $4,115.51 | 06/27/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968839 |
| Principal investigator 1 | ModernaTX, Inc. | $18,482.22 | 06/27/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968845 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $142.66 | 06/27/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH | A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien | No dispute reported | 06/30/2026 | 1190303115 |
| Principal investigator 1 | UCB SA | $7,335.25 | 06/27/2025 | Covered Recipient Physician | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS | No dispute reported | 06/30/2026 | 1246658592 |
| Principal investigator 1 | PFIZER INC. | $27,880.36 | 06/21/2025 | Non-covered Recipient Entity Altoona Center for Clinical Research PC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228793183 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,012.70 | 06/19/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184209129 |
| Principal investigator 1 | Aurinia Pharma U.S., Inc. | $1,900.00 | 06/18/2025 | Non-covered Recipient Entity Altoona Center for Clinical Research, PC | LUPKYNIS Registry Study | No dispute reported | 06/30/2026 | 1243930838 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,200.00 | 06/16/2025 | Non-covered Recipient Entity Altoona Center For Clinical Research PC Corp | A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1226137013 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $17,706.40 | 06/16/2025 | Non-covered Recipient Entity Altoona Center For Clinical Research PC Corp | A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1226137017 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,990.00 | 06/16/2025 | Non-covered Recipient Entity Altoona Center For Clinical Research PC Corp | A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1226137025 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,800.00 | 06/13/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEAR CH PC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175303316 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,197.14 | 06/12/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184206205 |
| Principal investigator 1 | PFIZER INC. | $41,212.68 | 06/06/2025 | Non-covered Recipient Entity Altoona Center for Clinical Research PC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228776985 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,269.73 | 06/05/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184204139 |
| Principal investigator 1 | UCB SA | $12,489.00 | 06/04/2025 | Covered Recipient Physician | A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. | No dispute reported | 06/30/2026 | 1246658610 |
| Principal investigator 1 | ABBVIE INC. | $1,255.15 | 06/03/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARC | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202487427 |
| Principal investigator 1 | Janssen Research & Development, LLC | $68.00 | 05/28/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265094 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,316.00 | 05/28/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265178 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,119.78 | 05/28/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184198831 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $11,466.00 | 05/28/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184198833 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,733.00 | 05/28/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184198835 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8.25 | 05/28/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223280450 |
| Principal investigator 1 | Eli Lilly and Company | $2,036.86 | 05/27/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | No dispute reported | 06/30/2026 | 1187874427 |
| Principal investigator 1 | Eli Lilly and Company | $4,314.00 | 05/23/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187874435 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,292.70 | 05/22/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184197551 |
| Principal investigator 1 | Amgen Inc. | $4,275.18 | 05/21/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL | A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome | No dispute reported | 06/30/2026 | 1246639087 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,118.60 | 05/21/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223280102 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,000.00 | 05/19/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEAR CH PC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-nave Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175303307 |
| Principal investigator 1 | Janssen Research & Development, LLC | $600.00 | 05/15/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEAR CH PC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175303274 |
| Principal investigator 1 | Janssen Research & Development, LLC | $600.00 | 05/15/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEAR CH PC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175303358 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,487.89 | 05/15/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184194605 |
| Recipient | Novartis Pharmaceuticals Corporation | $509.29 | 05/13/2025 | Covered Recipient Physician | Research Publication/Writing Support | No dispute reported | 06/30/2026 | 1190293790 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,507.40 | 05/09/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192147851 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,163.00 | 05/08/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184193727 |
| Principal investigator 1 | Aurinia Pharma U.S., Inc. | $155.00 | 05/07/2025 | Non-covered Recipient Entity Altoona Center for Clinical Research, PC | LUPKYNIS Registry Study | No dispute reported | 06/30/2026 | 1243930761 |
| Principal investigator 1 | Aurinia Pharma U.S., Inc. | $2,700.00 | 05/07/2025 | Non-covered Recipient Entity Altoona Center for Clinical Research, PC | LUPKYNIS Registry Study | No dispute reported | 06/30/2026 | 1243930763 |
| Principal investigator 1 | ABBVIE INC. | $8,632.35 | 05/06/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARC | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202481237 |
| Principal investigator 1 | PFIZER INC. | $72,623.06 | 04/29/2025 | Non-covered Recipient Entity Altoona Center for Clinical Research PC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228794089 |
| Principal investigator 1 | Eli Lilly and Company | $38,760.00 | 04/28/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187874429 |
| Principal investigator 1 | ModernaTX, Inc. | $17,026.74 | 04/28/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968805 |
| Principal investigator 1 | ModernaTX, Inc. | $12,158.64 | 04/28/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968809 |
| Principal investigator 1 | ModernaTX, Inc. | $4,278.68 | 04/28/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968811 |
| Principal investigator 1 | ModernaTX, Inc. | $3,001.17 | 04/28/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968833 |
| Principal investigator 1 | ModernaTX, Inc. | $772.20 | 04/28/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968835 |
| Principal investigator 1 | ModernaTX, Inc. | $217.62 | 04/28/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968843 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,059.89 | 04/28/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184190803 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,224.90 | 04/23/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184189147 |
| Principal investigator 1 | ModernaTX, Inc. | $1,750.00 | 04/16/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968785 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $14,328.79 | 04/15/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184183454 |
| Principal investigator 1 | ModernaTX, Inc. | $576.69 | 04/11/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968803 |
| Principal investigator 1 | ModernaTX, Inc. | $195.55 | 04/11/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968841 |
| Principal investigator 1 | PFIZER INC. | $77,252.64 | 04/10/2025 | Non-covered Recipient Entity Altoona Center for Clinical Research PC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228794187 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,895.26 | 04/08/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184182068 |
| Principal investigator 1 | Eli Lilly and Company | $245,665.29 | 04/07/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND CHRONIC LOW BACK PAIN (TRIUMPH-7) | No dispute reported | 06/30/2026 | 1187876223 |
| Principal investigator 1 | ABBVIE INC. | $1,328.45 | 04/03/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARC | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202471243 |
| Principal investigator 1 | PFIZER INC. | $1,878.80 | 04/01/2025 | Non-covered Recipient Entity Altoona Center for Clinical Research PC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228779460 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $13,881.35 | 04/01/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184180918 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,911.00 | 04/01/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184180920 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $405.32 | 04/01/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184180922 |
| Principal investigator 1 | UCB SA | $13,000.00 | 03/27/2025 | Non-covered Recipient Entity WEITZNER, YONKER, KAINE MD. | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | No dispute reported | 06/30/2026 | 1246657628 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $14,447.79 | 03/25/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184178878 |
| Principal investigator 1 | Eli Lilly and Company | $361,518.90 | 03/24/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE RETATRUTIDE TREATMENT IN THE MAINTENANCE OF WEIGHT REDUCTION IN INDIVIDUALS WITH OBESITY | No dispute reported | 06/30/2026 | 1187876221 |
| Principal investigator 1 | Amgen Inc. | $3,626.28 | 03/21/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH - 175 MEADOWBROOK LN | A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgrens Syndrome | No dispute reported | 06/30/2026 | 1246639079 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,520.00 | 03/21/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223276943 |
| Principal investigator 1 | UCB SA | $14,043.00 | 03/21/2025 | Non-covered Recipient Entity WEITZNER, YONKER, KAINE MD. | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS | No dispute reported | 06/30/2026 | 1246658372 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $11,233.60 | 03/19/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184174590 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $201.39 | 03/19/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184174592 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $657.96 | 03/19/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184174594 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,911.00 | 03/19/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184174596 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.20 | 03/19/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184174598 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,911.00 | 03/19/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184174600 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,000.00 | 03/14/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223276731 |
| Principal investigator 1 | Aurinia Pharma U.S., Inc. | $2,146.50 | 03/12/2025 | Non-covered Recipient Entity Altoona Center for Clinical Research, PC | LUPKYNIS Registry Study | No dispute reported | 06/30/2026 | 1243930990 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $4,541.00 | 03/11/2025 | Non-covered Recipient Entity Altoona Center For Clinical Research | A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus | No dispute reported | 06/30/2026 | 1235999085 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,875.00 | 03/11/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184170902 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,423.00 | 03/10/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEAR CH PC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175303340 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,000.00 | 03/10/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEAR CH PC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175303375 |
| Principal investigator 1 | ABBVIE INC. | $4,780.60 | 03/06/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARC | M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202456965 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,635.00 | 03/05/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175264947 |
| Principal investigator 1 | Janssen Research & Development, LLC | $68.00 | 03/05/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175264956 |
| Principal investigator 1 | Janssen Research & Development, LLC | $68.00 | 03/05/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175264973 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,635.00 | 03/05/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265046 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,635.00 | 03/05/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265076 |
| Principal investigator 1 | Janssen Research & Development, LLC | $68.00 | 03/05/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265125 |
| Principal investigator 1 | Janssen Research & Development, LLC | $68.00 | 03/05/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265141 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,635.00 | 03/05/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265162 |
| Principal investigator 1 | Janssen Research & Development, LLC | $68.00 | 03/05/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265200 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,635.00 | 03/05/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265216 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $14,996.38 | 03/04/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184156766 |
| Principal investigator 1 | UCB SA | $53.89 | 02/27/2025 | Non-covered Recipient Entity WEITZNER, YONKER, KAINE MD. | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS | No dispute reported | 06/30/2026 | 1246658442 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $15.00 | 02/25/2025 | Non-covered Recipient Entity Altoona Center For Clinical Research | A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus | No dispute reported | 06/30/2026 | 1235999083 |
| Principal investigator 1 | Eli Lilly and Company | $2,472.72 | 02/25/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187872941 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10,336.34 | 02/25/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184155388 |
| Principal investigator 1 | Janssen Research & Development, LLC | $35.00 | 02/24/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265060 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 02/24/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265068 |
| Principal investigator 1 | Janssen Research & Development, LLC | $35.00 | 02/24/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265191 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $6,545.00 | 02/20/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH | An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment | No dispute reported | 06/30/2026 | 1190306179 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,443.85 | 02/18/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184154172 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,400.00 | 02/13/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184153914 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $750.00 | 02/13/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184153916 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,100.00 | 02/13/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184153918 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $59.07 | 02/13/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184153920 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $146.80 | 02/13/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184153922 |
| Principal investigator 1 | ABBVIE INC. | $4,056.85 | 02/05/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARC | M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202444606 |
| Principal investigator 1 | AstraZeneca UK Limited | $21,161.15 | 02/05/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH | A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment | No dispute reported | 06/30/2026 | 1185546153 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 02/05/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968795 |
| Principal investigator 1 | ModernaTX, Inc. | $800.00 | 02/05/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968831 |
| Principal investigator 1 | ModernaTX, Inc. | $7,000.00 | 02/05/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968847 |
| Principal investigator 1 | PFIZER INC. | $1,240.00 | 02/05/2025 | Non-covered Recipient Entity Altoona Center for Clinical Research PC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228762273 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $20,228.81 | 02/05/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184152430 |
| Principal investigator 1 | ABBVIE INC. | $1,800.00 | 02/04/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARC | M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202443739 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,000.00 | 02/03/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEAR CH PC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175303290 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.00 | 02/03/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEAR CH PC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175303348 |
| Principal investigator 1 | Eli Lilly and Company | $1,157.44 | 01/31/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | No dispute reported | 06/30/2026 | 1187872939 |
| Principal investigator 1 | Eli Lilly and Company | $661.22 | 01/31/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | No dispute reported | 06/30/2026 | 1187875563 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $39,822.00 | 01/30/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH | An Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab Infusion in Adults With Giant Cell Arteritis (GCA) or Polymyalgia Rheumatica (PMR) | No dispute reported | 06/30/2026 | 1190306181 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,330.02 | 01/29/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184149846 |
| Principal investigator 1 | UCB SA | $72,121.00 | 01/29/2025 | Non-covered Recipient Entity WEITZNER, YONKER, KAINE MD. | A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. | No dispute reported | 06/30/2026 | 1246657380 |
| Principal investigator 1 | Eli Lilly and Company | $7,810.00 | 01/28/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187875853 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $3,620.76 | 01/28/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH | A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome | No dispute reported | 06/30/2026 | 1190306019 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $229,384.33 | 01/28/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH | A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease | No dispute reported | 06/30/2026 | 1190306183 |
| Principal investigator 1 | Eli Lilly and Company | $3,025.22 | 01/27/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | No dispute reported | 06/30/2026 | 1187875565 |
| Principal investigator 1 | ModernaTX, Inc. | $2,026.44 | 01/27/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968779 |
| Principal investigator 1 | ModernaTX, Inc. | $1,487.07 | 01/27/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968799 |
| Principal investigator 1 | ModernaTX, Inc. | $634.55 | 01/27/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968807 |
| Principal investigator 1 | ModernaTX, Inc. | $3,468.41 | 01/27/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968813 |
| Principal investigator 1 | ModernaTX, Inc. | $18,007.02 | 01/27/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968821 |
| Principal investigator 1 | ModernaTX, Inc. | $772.20 | 01/27/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968827 |
| Principal investigator 1 | UCB SA | $900.00 | 01/27/2025 | Non-covered Recipient Entity WEITZNER, YONKER, KAINE MD. | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | No dispute reported | 06/30/2026 | 1246657085 |
| Principal investigator 1 | PFIZER INC. | $240.00 | 01/25/2025 | Non-covered Recipient Entity Altoona Center for Clinical Research PC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228798861 |
| Principal investigator 1 | PFIZER INC. | $2,045.12 | 01/22/2025 | Non-covered Recipient Entity Altoona Center for Clinical Research PC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228802068 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,675.78 | 01/21/2025 | Non-covered Recipient Entity Altoona Center For Clinical Research | A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus | No dispute reported | 06/30/2026 | 1235999081 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $299.59 | 01/21/2025 | Non-covered Recipient Entity Altoona Center For Clinical Research | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment | No dispute reported | 06/30/2026 | 1235999091 |
| Principal investigator 1 | Eli Lilly and Company | $143,170.00 | 01/21/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | No dispute reported | 06/30/2026 | 1187871955 |
| Principal investigator 1 | Eli Lilly and Company | $131,215.00 | 01/21/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | No dispute reported | 06/30/2026 | 1187874431 |
| Principal investigator 1 | Eli Lilly and Company | $26,062.00 | 01/21/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187874433 |
| Principal investigator 1 | Eli Lilly and Company | $125,103.00 | 01/21/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-1) | No dispute reported | 06/30/2026 | 1187880661 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $961,365.84 | 01/21/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH | An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment | No dispute reported | 06/30/2026 | 1190303113 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10,700.48 | 01/21/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184149048 |
| Principal investigator 1 | UCB SA | $420.56 | 01/21/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH - RESEARCH | A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. | No dispute reported | 06/30/2026 | 1246658304 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,565.62 | 01/17/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184148079 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $81,650.00 | 01/16/2025 | Non-covered Recipient Entity Altoona Center For Clinical Research | A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1) | No dispute reported | 06/30/2026 | 1235999093 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $5,022.17 | 01/15/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH | A Randomized, Double-blind, Placebo Controlled, 2-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-1) | No dispute reported | 06/30/2026 | 1190306185 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 01/15/2025 | Non-covered Recipient Entity Altoona Center for Clinical Research PC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228800523 |
| Principal investigator 1 | Amgen Inc. | $1,278,572.61 | 01/14/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH - 175 MEADOWBROOK LN | A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants | No dispute reported | 06/30/2026 | 1246639085 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $7,554.00 | 01/13/2025 | Non-covered Recipient Entity Altoona Center For Clinical Research | A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1235999087 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,135.00 | 01/13/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175264931 |
| Principal investigator 1 | Janssen Research & Development, LLC | $160.00 | 01/13/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175264940 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,757.00 | 01/13/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175264965 |
| Principal investigator 1 | Janssen Research & Development, LLC | $68.00 | 01/13/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175264992 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,316.00 | 01/13/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265022 |
| Principal investigator 1 | Janssen Research & Development, LLC | $271.00 | 01/13/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265085 |
| Principal investigator 1 | Janssen Research & Development, LLC | $68.00 | 01/13/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265109 |
| Principal investigator 1 | Janssen Research & Development, LLC | $68.00 | 01/13/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265116 |
| Principal investigator 1 | Janssen Research & Development, LLC | $160.00 | 01/13/2025 | Non-covered Recipient Entity Altoona Spclty Ctr Llc | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175265207 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,704.62 | 01/13/2025 | Non-covered Recipient Entity Altoona Center For Clinical Research PC Corp | A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1226136969 |
| Principal investigator 1 | Eli Lilly and Company | $141.90 | 01/09/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187874323 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $68,580.00 | 01/09/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH | A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease | No dispute reported | 06/30/2026 | 1190303119 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,953.03 | 01/09/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH | A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome | No dispute reported | 06/30/2026 | 1190303121 |
| Principal investigator 1 | PFIZER INC. | $4,172.85 | 01/09/2025 | Non-covered Recipient Entity Altoona Center for Clinical Research PC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228799624 |
| Principal investigator 1 | Amgen Inc. | $25,038.06 | 01/08/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH - 175 MEADOWBROOK LN | A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome | No dispute reported | 06/30/2026 | 1246639081 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $39,115.00 | 01/08/2025 | Non-covered Recipient Entity Altoona Center For Clinical Research | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment | No dispute reported | 06/30/2026 | 1235999095 |
| Principal investigator 1 | Eli Lilly and Company | $72,941.00 | 01/07/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | No dispute reported | 06/30/2026 | 1187876219 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $23,860.69 | 01/07/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184145778 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10,700.48 | 01/07/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARCH PC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184145780 |
| Principal investigator 1 | ABBVIE INC. | $3,650.40 | 01/02/2025 | Non-covered Recipient Entity ALTOONA CENTER FOR CLINICAL RESEARC | M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202434295 |